{"id":"db-1303-bnt323","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL5756759","moleculeType":null,"molecularWeight":"479.47"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This bispecific antibody is designed to bind two different immune regulatory targets, thereby overcoming single-checkpoint inhibition limitations and potentially generating more robust anti-tumor immunity. By engaging multiple pathways simultaneously, the drug aims to improve efficacy in checkpoint-resistant tumors and expand the patient population that can benefit from immunotherapy.","oneSentence":"DB-1303/BNT323 is a bispecific antibody that simultaneously engages two distinct immune checkpoints to enhance anti-tumor T-cell responses.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:42:30.289Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced or metastatic solid tumors (Phase 3 development)"}]},"trialDetails":[{"nctId":"NCT06018337","phase":"PHASE3","title":"A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)","status":"ACTIVE_NOT_RECRUITING","sponsor":"DualityBio Inc.","startDate":"2024-01-18","conditions":"Metastatic Breast Cancer","enrollment":541},{"nctId":"NCT06340568","phase":"PHASE3","title":"A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2025-06-10","conditions":"Endometrial Cancer","enrollment":480},{"nctId":"NCT05150691","phase":"PHASE1, PHASE2","title":"A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors","status":"RECRUITING","sponsor":"DualityBio Inc.","startDate":"2022-01-31","conditions":"HER2-positive Advanced Solid Tumor","enrollment":796},{"nctId":"NCT06265428","phase":"PHASE3","title":"A Study to Compare DB-1303/BNT323 Versus T-DM1 in Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"DualityBio Inc.","startDate":"2024-01-29","conditions":"HER2-positive Breast Cancer","enrollment":228}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"DB-1303/BNT323","genericName":"DB-1303/BNT323","companyName":"DualityBio Inc.","companyId":"dualitybio-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DB-1303/BNT323 is a bispecific antibody that simultaneously engages two distinct immune checkpoints to enhance anti-tumor T-cell responses. Used for Advanced or metastatic solid tumors (Phase 3 development).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}